CHRNA4 and attention deficit-hyperactivity disorder: The heteromeric α4β2 is the most abundant nAChR subtype in central nervous system along with the homomeric α7 receptor and is considered to be an important target for treating numerous neurological impairments including schizophrenia, attention deficit hyperactivity disorder (ADHD) and pain [3–6].